NEW YORK, April 26, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GPN, HMSY, INFO, and IDXG which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market today, WallStEquities.com covers the following stocks: Global Payments Inc. (NYSE: GPN), HMS Holdings Corp. (NASDAQ: HMSY), IHS Markit Ltd (NASDAQ: INFO), and Interpace Diagnostics Group Inc. (NASDAQ: IDXG). Companies in the Business Services sector provide support services, such as office administration, hiring and placing of personnel, security services, travel arrangement, cleaning, and waste disposal, to businesses. All you have to do is sign up today for this free limited time offer by clicking the link below.
Atlanta, Georgia headquartered Global Payments Inc.'s stock finished Wednesday's session 0.11% lower at $109.53 with a total trading volume of 743,287 shares. The stock has gained 33.61% in the previous twelve months. The Company's shares are trading above their 200-day moving average by 6.88%. Moreover, shares of Global Payments, which provides payment technology and software solutions for credit cards, debit cards, electronic payments, and check-related services, have a Relative Strength Index (RSI) of 43.20.
On April 09th, 2018, Global Payments announced that it will release its Q1 2018 results before the market opens on May 03rd, 2018. Management will host a conference call for investors at 8:00 a.m. ET that same day to discuss these results. The call may be accessed under the investor relations page of the Company's website. Get the full research report on GPN for free by clicking below at: www.wallstequities.com/registration/?symbol=GPN
Shares in Irving, Texas headquartered HMS Holdings Corp. rose 0.56%, ending yesterday's session at $18.10 with a total trading volume of 256,787 shares. The stock has gained 5.60% in the past month. The Company's shares are trading above their 50-day and 200-day moving averages by 7.63% and 2.86%, respectively. Moreover, shares of HMS Holdings, which through its subsidiaries, provides cost containment solutions in the US healthcare marketplace, have an RSI of 65.64.
On April 17th, 2018, HMS Holdings announced that it will report its Q1 2018 financial and operating results on May 04th, 2018, at 8:30 a.m. ET. Supplemental financial information, including the press release and investor presentation, will be released at approximately 6:00 a.m. ET that same day and will also be available on the Company's Investor Relations website. Download our actionable research report on HMSY at: www.wallstequities.com/registration/?symbol=HMSY
On Wednesday, London, the UK headquartered IHS Markit Ltd's stock saw a drop of 0.69%, to close the day at $48.77. A total volume of 1.43 million shares was traded. The Company's shares have advanced 11.45% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.78% and 5.82%, respectively. Additionally, shares of IHS Markit, which provides critical information, analytics, and solutions for various industries and markets that drive economies worldwide, have an RSI of 52.37.
On April 12th, 2018, IHS Markit announced that it has been appointed as the independent benchmark administrator for Danish bond indices from Nordea Bank, the largest financial services group in the Nordic region. Nordea Bank will use IHS Markit Index Administration Services for its benchmark calculations, methodologies, periodic auditing, and data distribution on indices referencing Danish government and mortgage bonds. Register for your free report coverage on INFO at: www.wallstequities.com/registration/?symbol=INFO
Interpace Diagnostics Group
Shares in Parsippany, New Jersey headquartered Interpace Diagnostics Group Inc. ended the day 0.63% higher at $0.90. A total volume of 114,770 shares was traded. The Company's shares are trading below their 50-day moving average by 6.30%. Furthermore, shares of Interpace Diagnostics, which develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers, have an RSI of 43.82.
On April 18th, 2018, Interpace Diagnostics reported that it has entered into an Agreement with BJC Healthcare of St. Louis, Missouri, one of the largest non-profit, integrated healthcare systems in the US. The Agreement enables all physicians across the BJC system access to both ThyGenX® and ThyraMIR® for patients with indeterminate thyroid nodules. Get the free research report on IDXG at: www.wallstequities.com/registration/?symbol=IDXG
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities